Phathom patents expiration
1. Voquezna Dual Pak patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7977488 | PHATHOM | 1-heterocyclylsulfonyl, 2-aminomethyl, 5-(hetero-) aryl substituted 1-H-pyrrole derivatives as acid secretion inhibitors |
Aug, 2028
(4 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9186411 | PHATHOM | Pharmaceutical composition |
Aug, 2030
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | May 3, 2027 |
| Generating Antibiotic Incentives Now (GAIN) | May 3, 2032 |
Drugs and Companies using AMOXICILLIN; VONOPRAZAN FUMARATE ingredient
NCE-1 date: 2031-05-04
Market Authorisation Date: 03 May, 2022
Treatment: NA
Dosage: CAPSULE, TABLET;ORAL
More Information on Dosage
VOQUEZNA DUAL PAK family patents
2. Voquezna Triple Pak patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7977488 | PHATHOM | 1-heterocyclylsulfonyl, 2-aminomethyl, 5-(hetero-) aryl substituted 1-H-pyrrole derivatives as acid secretion inhibitors |
Aug, 2028
(4 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9186411 | PHATHOM | Pharmaceutical composition |
Aug, 2030
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | May 3, 2027 |
| Generating Antibiotic Incentives Now (GAIN) | May 3, 2032 |
Drugs and Companies using AMOXICILLIN; CLARITHROMYCIN; VONOPRAZAN FUMARATE ingredient
NCE-1 date: 2031-05-04
Market Authorisation Date: 03 May, 2022
Treatment: NA
Dosage: CAPSULE, TABLET, TABLET;ORAL
More Information on Dosage
VOQUEZNA TRIPLE PAK family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic